Avaliação da atividade e do mecanismo de ação antileucêmica da cantinona
Ano de defesa: | 2014 |
---|---|
Autor(a) principal: | |
Orientador(a): | |
Banca de defesa: | |
Tipo de documento: | Dissertação |
Tipo de acesso: | Acesso aberto |
Idioma: | por |
Instituição de defesa: |
Universidade Federal de Mato Grosso
Brasil Faculdade de Medicina (FM) UFMT CUC - Cuiabá Programa de Pós-Graduação em Ciências da Saúde |
Programa de Pós-Graduação: |
Não Informado pela instituição
|
Departamento: |
Não Informado pela instituição
|
País: |
Não Informado pela instituição
|
Palavras-chave em Português: | |
Link de acesso: | http://ri.ufmt.br/handle/1/488 |
Resumo: | Torquato, H.F.V. Evaluation of the activity and mechanism of action antileukemic of canthinone. 2014. 73 f. Dissertation submitted to the Health Science Post Graduate Programs Coordination of the School of Medicine of the Federal University of Mato Grosso, as a partial requirement for the degree of Master in Health Sciences. Pharmacology Area. Acute myeloid leukemia (AML) is a malignant proliferative disease, where the leukemic cells do not complete the cell differentiation process. The standard therapy of AML includes intensive chemotherapy despite of its association with a low rate of remission afterward, it is also has been considered as long-term treatment with a significant toxicity. Therefore, a development of new therapeutic approaches might impact on treatment of AML. The canthinone (Cant) is a beta-carbonyl subclass of alkaloids isolated from plants, specifically Simaroubaceae and Rutaceae families. Certain activities such as antiulcer, antibacterial and antifungal were referred to Cant, whereas other activities [cytotoxic, antimalarial and antiviral] referred to some forms of its synthetic analogues. The aim of this study is to investigate the antitumor potential of Cant in AML cell lines. For this, the cytotoxic activity was performed in the lines Kasumi-1 and KG-1 marked by annexin V and PI after treatment with Cant (28, 56, 113 and 227 μM) for 24 h., where the action of its antitumor mechanism it action was investigated in Kasumi-1 cells (45 μM). The action of the alkaloid on different cell parameters was evaluated, such as the integrity of lysosomal and mitochondrial membranes, caspases 3, 8 and 9 activation, expression of important proteins related to cell survival (ERK1/2 and Bcl-2). In addition, we evaluated the ability of Cant (14 μM) to induce myeloid differentiation in both cell lines. The results showed that Cant has a potential antitumor activity with IC50 of 38.9 ± 1 μM for Kasumi-1 and 39.1±1 μM for KG-1. As well as a lysosomal permeabilization effect demonstrated by leakage of acridine orange dye from the lysosomes to cytosol, causing a drop of 54.6% (p< 0.001) in the mitochondrial membrane potential. The activation of caspases 3 and 8 were followed by an increase in fluorescence at 2.4 (p< 0.01) and 2.5 (p< 0.05) times respectively, compared to untreated cells, and caspase 9 (p< 0.01) increased 2.1 times the signal. The protein expression of ERK 1/2 and Bcl-2 was reduced, more expressively from 45 μM of Cant (43%, p<0.01) on ERK 1/2 and 135 μM of Cant (53 %, p<0.01) on Bcl-2. In the evaluation of cell differentiation, an increase of 2.5 times (p<0.001) noticed with the expression of CD15+ and CD 11b+ in Kasumi-1 cells treated with Cant (14 μM) compared to untreated cells. However, the results shows a decrease in the expression of leukemic stem cell markers (CD34+ CD38-Lin-) with approximately 7-fold (p <0.001) in comparison with control. In KG-1 cell line treated with Cant (14 μM), CD15+ expression rose up to 2.5 times (p<0.001). The expression of leukemic stem cells markers was doubled (p<0.001) with no difference in CD11b+. All these data has been shown, that Cant has antitumor activity in AML cells via cell death mechanism through activation of the extrinsic and intrinsic pathways of apoptosis, possibly with a greater contribution of the mitochondrial pathway with a significant lysosomal role. In addition to its effects on the proliferation of leukemic cells, Cant showed a significant action on cell differentiation, which qualifies it as a candidate for antitumor drug for AML treatment, where the disease therapy can be based on differentiation. |